

Silvia Marsoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4962850/publications.pdf>

Version: 2024-02-01

60
papers

10,381
citations

125106

35
h-index

139680

61
g-index

61
all docs

61
docs citations

61
times ranked

15540
citing authors

#	ARTICLE	IF	CITATIONS
1	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. <i>Cancers</i> , 2022, 14, 241.	1.7	14
2	Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study. <i>Cancers</i> , 2022, 14, 1197.	1.7	9
3	Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. <i>British Journal of Cancer</i> , 2022, 127, 394-407.	2.9	41
4	Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. <i>Cancer Discovery</i> , 2022, 12, 1656-1675.	7.7	48
5	Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	3.2	11
6	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 897-912.	2.7	6
7	Precision oncology in metastatic colorectal cancer – from biology to medicine. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 506-525.	12.5	113
8	Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3506.	0.8	53
9	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. <i>Cancer Cell</i> , 2021, 39, 708-724.e11.	7.7	175
10	Empowering Clinical Decision Making in Oligometastatic Colorectal Cancer: The Potential Role of Drug Screening of Patient-Derived Organoids. <i>JCO Precision Oncology</i> , 2021, 5, 1192-1199.	1.5	5
11	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	3.0	25
12	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. <i>Clinical Cancer Research</i> , 2020, 26, 1372-1384.	3.2	66
13	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. <i>ESMO Open</i> , 2020, 5, e000911.	2.0	94
14	Radiomics predicts response of individual HER2-amplified colorectal cancer liver metastases in patients treated with HER2-targeted therapy. <i>International Journal of Cancer</i> , 2020, 147, 3215-3223.	2.3	27
15	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. <i>Cancer Discovery</i> , 2020, 10, 1129-1139.	7.7	245
16	Central Nervous System as Possible Site of Relapse in ERBB2-Positive Metastatic Colorectal Cancer. <i>JAMA Oncology</i> , 2020, 6, 927.	3.4	20
17	Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, 256-262.e2.	1.0	56
18	Impact of inter-reader contouring variability on textural radiomics of colorectal liver metastases. <i>European Radiology Experimental</i> , 2020, 4, 62.	1.7	29

#	ARTICLE	IF	CITATIONS
19	The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4124-TPS4124.	0.8	14
20	Plasma HER2 (<i>ERBB2</i>) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 3046-3053.	3.2	112
21	HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2019, 24, 1395-1402.	1.9	95
22	Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. <i>ESMO Open</i> , 2019, 4, e000572.	2.0	27
23	Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies. <i>Cancer Treatment Reviews</i> , 2019, 73, 41-53.	3.4	69
24	Early-onset colorectal cancer in young individuals. <i>Molecular Oncology</i> , 2019, 13, 109-131.	2.1	365
25	Pembrolizumab in MMR-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status: The ARETHUSA trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS2659-TPS2659.	0.8	10
26	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 148-162.e7.	7.7	129
27	Integrating liquid biopsies into the management of cancer. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 531-548.	12.5	1,375
28	Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. <i>Nature</i> , 2017, 552, 116-120.	13.7	480
29	Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 738-746.	5.1	778
30	<i>KRAS</i> mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. <i>Oncotarget</i> , 2015, 6, 34014-34022.	0.8	68
31	Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015, 21, 795-801.	15.2	809
32	A lesson from vorinostat in pleural mesothelioma. <i>Lancet Oncology</i> , The, 2015, 16, 359-360.	5.1	2
33	The genomic landscape of response to EGFR blockade in colorectal cancer. <i>Nature</i> , 2015, 526, 263-267.	13.7	398
34	Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015, 28, 1481-1491.	2.9	226
35	Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , 2014, 20, 5663-5671.	3.2	15
36	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , The, 2013, 14, 981-988.	5.1	472

#	ARTICLE	IF	CITATIONS
37	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. <i>European Journal of Cancer</i> , 2013, 49, 290-296.	1.3	74
38	A Phase II Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Pretreated Patients with Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1091-1094.	0.5	51
39	Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors. <i>Journal of Clinical Oncology</i> , 2012, 30, 996-1004.	0.8	68
40	Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas. <i>Clinical Cancer Research</i> , 2012, 18, 2515-2525.	3.2	172
41	An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 792-800.	1.2	20
42	A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies. <i>Acta Oncologica</i> , 2011, 50, 1105-1110.	0.8	13
43	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 863-875.	3.0	469
44	A Molecularly Annotated Platform of Patient-Derived Xenografts (â€œXenopatientsâ€) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer. <i>Cancer Discovery</i> , 2011, 1, 508-523.	7.7	818
45	New Omics Information for Clinical Trial Utility in the Primary Setting. <i>Journal of the National Cancer Institute Monographs</i> , 2011, 2011, 128-133.	0.9	4
46	Testing Epidermal Growth Factor Receptor Mutations in Patients With Nonâ€Small-Cell Lung Cancer to Choose Chemotherapy: The Other Side of the Coin. <i>Journal of Clinical Oncology</i> , 2011, 29, 3835-3837.	0.8	16
47	Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 399-411.	1.1	35
48	Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study. <i>Clinical Cancer Research</i> , 2010, 16, 2474-2482.	3.2	54
49	Role of Cetuximab in the Treatment of Patients With NSCLC: Are We Throwing Out the Baby With the Bath Water?. <i>Journal of Clinical Oncology</i> , 2010, 28, e467-e467.	0.8	1
50	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3219-3226.	0.8	1,352
51	Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine. <i>Journal of Clinical Oncology</i> , 2010, 28, 4554-4561.	0.8	47
52	Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to \pm 1-acid glycoprotein plasma levels. <i>European Journal of Cancer</i> , 2010, 46, 505-516.	1.3	15
53	Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. <i>European Journal of Cancer</i> , 2006, 42, 171-178.	1.3	39
54	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. <i>Journal of Clinical Oncology</i> , 2005, 23, 1867-1874.	0.8	163

#	ARTICLE	IF	CITATIONS
55	Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy—a multicenter randomized trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 78-92.	0.4	112
56	Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. <i>Lancet, The</i> , 1998, 351, 1677-1681.	6.3	81
57	Fluorouracil and folinic acid in colon cancer. <i>Lancet, The</i> , 1995, 345, 1582-1583.	6.3	29
58	Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results. <i>Cancer Treatment Reviews</i> , 1991, 18, 37-46.	3.4	12
59	Tiazofurin: A new antitumor agent. <i>Investigational New Drugs</i> , 1984, 2, 79-84.	1.2	32
60	Spiromustine: a new agent entering clinical trials. <i>Investigational New Drugs</i> , 1983, 1, 303-8.	1.2	11